ClinicalTrials.gg
CompletedNCT06294470Updated Mar 5, 2024

Efficacy of Stapled Hemorrhoidopexy for the Treatment of Obstructive Defecation Syndrome

An interventional study of Ballon expulsion test and Colonic transit time in Hemorrhoids and Defecation Disorder, sponsored by Universidad Central de Venezuela. Completed at 1 site in Venezuela. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Universidad Central de Venezuela · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2023, registered Jan 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The objective of this study is to assess the efficiency of the procedure for hemorrhoidal prolapse and pexia in alleviating symptoms of defecatory obstruction among patients with grade II to IV mucohemorrhoidal prolapse.

Read the detailed description

In 1998, Longo introduced a new technique called the stapled hemorrhoidal prolapse and pexia procedure (PPH) to treat mucohemorrhoidal disease. According to Longo, hemorrhoidal prolapse is always associated with internal rectal prolapse, which can be a symptom of defecation obstruction syndrome. The PPH technique aims to correct these symptoms by removing the mucosal segment and pexiing the hemorrhoids, thus eliminating excess rectal tissue. This improves the resting surface tension of the rectal mucosa, making defecation easier and improving defecatory obstruction.

The research focused on applying theoretical concepts related to defecatory obstruction secondary to mucohemorrhoidal prolapse, which results in difficulties with an adequate defecatory act. The main objective was to determine if surgery for hemorrhoidal prolapse and pexia could correct the symptoms of obstructed defecation, as proposed by Longo. The study established facilities to evaluate and provide pre- and postoperative follow-up to patients with symptoms of defecatory obstruction. The research question posed was: "In patients with mucohemorrhoidal disease and symptoms of defecatory obstruction, can the PPH technique improve the symptoms of defecatory obstruction?"

To carry out the research, a questionnaire was used to collect epidemiological, clinical, and functional data from patients with grade II to IV mucohemorrhoidal disease who had surgical indication for PPH. The Constipation Scores questionnaire (Altomare and Agachan-Wexner) was used to identify patients with symptoms of defecatory obstruction. The sample was divided into two groups: an experimental group, which included patients with symptoms of defecatory obstruction, and a control group, made up of patients without such symptoms. Functional studies were carried out, such as colonic transit time and the balloon expulsion test. Subsequently, the PPH technique was performed, and after one month postoperatively, the Constipation Scores and functional studies were evaluated to determine if there was an improvement in the initial scores.

The study was designed as a quasi-experimental study and was also supported by an analytical case-control study. Its aim was to assess patients with grades II to IV mucohemorrhoidal disease who required PPH.

02

Conditions studied

  • Hemorrhoids
  • Defecation Disorder

Browse trials for

Keywords

  • Hemorrohoids
  • Obstructive Defecation Syndrome
  • Stapled hemorrhoidopexy
03

In context

Hemorrhoids

238 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

This study's enrollment of 34 is below the median of 100 across 183 interventional studies indexed under Hemorrhoids.

Browse Hemorrhoids studies →

Lead sponsor

Universidad Central de Venezuela is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 70 years old.
  • Patients diagnosed with grade II to IV mucohemorrhoidal disease and suffering from symptoms of obstructed defecation, which require a procedure for prolapse and hemorrhoidal pexia.
  • Patients with a minimum Altomare Score of 3pts and Agachan Score Wexner of at least 12pts.

Exclusion criteria

Exclusion Criteria:

  • Patients who, after undergoing a colonic transit time study, are found to have a different type of constipation (such as slow transit or colonic inertia).
  • Patients who undergo PPH technique along with another anorectal procedure.
  • Patients with any other anorectal conditions, including fistula, anal fissure, inflammatory bowel disease, chronic diarrhea, or malignant lesions.
  • Patients diagnosed with mucohemorrhoidal disease and experiencing acute complications.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Experimental

    Altomare Score score ≥3pts and Agachan Wexner Score ≥12pts

    Diagnostic Test: Ballon expulsion test · Diagnostic Test: Colonic transit time · Procedure: Stapled hemorrhodopexy

  • Active comparator
    Control

    Altomare Score score \<3pts and Agachan Wexner Score \<12pts

    Diagnostic Test: Ballon expulsion test · Diagnostic Test: Colonic transit time · Procedure: Stapled hemorrhodopexy

Interventions

  • Diagnostic testBallon expulsion test

    Rectal latex balloon probe filled with saline solution. Patients expelled balloon and time recorded (\<1 or \>1 min).

  • Diagnostic testColonic transit time

    Patients ingested capsules with 24 radiopaque markers and underwent standing abdominal radiographs on Day 3 and Day 5. Over 80% expulsion within five days was considered normal, while retention indicated defecatory obstruction.

  • ProcedureStapled hemorrhodopexy

    Circumferential stapled hemorrhoidopexy with a 34mm circular stapler is a surgical procedure used to treat mucohemorrhoidal prolapse.

06

What researchers measure

Primary outcomes

  1. Postoperative improvement of symptoms of defecatory obstruction

    Change From Baseline in Altomare Score and Agachan Wexner Score \[Time Frame: 1 month\]. Altomare Score: Assessed using an interviewer-led questionnaire with eight items (time spent at toilet, attempts to defecate each day, digitation, laxatives, enemas, straining, consistency, completeness), each rated on a 3- or 4-point Likert scale. Scores range from 0 (no symptoms) to 3 or 4 (severe symptoms), with a max score of 31 indicating obstructive defecatory syndrome (\>3). Higher scores denote worse symptoms. Agachan Wexner Score: Derived from eight variables (Frequency of bowel movements, effort, Completeness, pain, time, assistance, failure, history), scored from 0 to 4 (except "assistance for defecation," 0-2). Global score is the sum, with \>12 indicating constipation symptoms. Higher scores indicate worse defecatory obstruction symptoms.

    Time frame: 1 month

Secondary outcomes

  1. Postoperative change of the balloon expulsion test

    Time recorded (\<1 or \>1 min) in ballon expulsion test in control and experimental group.

    Time frame: 1 month

  2. Postoperative change of the colonic transit time

    Over 80% expulsion of 24 radiopaque markers on standing abdominal radiographs within five days

    Time frame: 1 month

07

Study locations

1 site
  • Hospital Domingo Luciani
    Caracas, Miranda 1073, Venezuela
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2023, 6 months.

Of 65 non-industry interventional studies with no phase under Hemorrhoids, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 6 months is below that.

Counting every sponsor, half of 70 studies reached it within 23 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Mar 5, 2024
StartActual
May 1, 2023
Primary completionActual
Nov 30, 2023
CompletionActual
Dec 15, 2023
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06294470
Lead sponsor
Universidad Central de Venezuela
Responsible party
Cristopher Varela (M.D., Universidad Central de Venezuela) — Principal investigator
First posted
Mar 5, 2024
Start date
May 1, 2023
Primary completion
Nov 30, 2023
Completion
Dec 15, 2023
Last update
Mar 5, 2024

Study contacts

Cristopher Varela, MD
principal investigator · Instituto Venezolano de los Seguros Sociales

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion